National Cancer Institute

FDA approves revolutionary blood cancer treatmentFDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma (cHL) is the first new advanced treatment for the disease in 40 years
How vaping affects the ocular surfaceElectronic cigarettes (e-cigarettes) are devices designed to deliver nicotine in a solution rather than smoke without tobacco combustion. Perceived by consumers as a safer alternative to conventional cigarettes, e-cigarettes are aggressively marketed as lifestyle-choice consumables.
Number of women with metastatic breast cancer rising, as is survival rateStudy highlights the need for services and research for this understudied population.
New study says cancer survivors incur debt and have to tap alternate sources of income to pay for treatmentThe average cancer survivor with insurance incurs $712 in monthly bills for physician copayments, prescription drugs and other expenses related to treatment, according to a new study from Washington National’s Institute for Wellness Solutions.
Tumor classification using molecular signaturesClassifying malignant tumors has typically relied on pathologic criteria from the tissue site of origin with histologic and other clinical characteristics of the tumor determining the target and type of therapeutic intervention. This approach to classifying cancer, however, is slowly being rethought.
Phase I clinical trials test new therapies for kids’ cancersEarly phase pediatric cancer trials offer hope to children whose cancer defies standard therapy.
NSAID use can reduce breast cancer recurrence in overweight, obese womenOverweight and obese postmenopausal breast cancer patients taking aromatase inhibitors may gain a significant benefit by adding nonsteroidal anti-inflammatory drugs (NSAIDs) to their treatment, according to a study published in the August 14 issue of Cancer Research.
[BLOG] Blessings in disguise Should formularies welcome premium-priced bladder cancer drugs?The management of bladder cancer represents one of the most costly and underestimated challenges in the oncology spectrum. Despite having the 6th highest incidence of any cancer in the United States, high recurrence rates and the need to constantly monitor patients act as the primary drivers for the high expenditures associated with the disease.
Immunotherapy method effective against various cancersResearchers have developed a new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient’s cancer.
Advanced stomach cancer drug approvedFDA approved ramucirumab (Cyramza, Eli Lilly) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma.